Gas chromatography-mass spectrometry (GC-MS) is a powerful tool for e-liquid analysis, but it answers a defined analytical question rather than proving that an entire product is safe, stable or consistently manufactured.
The distinction matters. A laboratory can identify major flavouring analytes under a specified method while still needing separate evidence for method performance, batch release, storage stability, aerosol emissions and device compatibility.
This guide explains what the main standards and guidance actually cover. It also separates independent sources from YTOO’s own claims about its laboratory and production systems.
What WHO SOP 16 actually standardizes
The World Health Organization’s TobLabNet SOP 16, published in 2025, is a non-targeted GC-MS method for determining flavouring agents in e-liquids. WHO says it is suitable for identifying the main analytes and includes optional verification and semi-quantitative assessment.
That is narrower than a general quality certificate. SOP 16 supports tobacco-product regulation and comparable laboratory work; it does not certify a factory, validate every in-house method, establish shelf life or show what a particular device will produce in its aerosol. The earlier claim that SOP 16 standardized analytical capability across the vaping industry went beyond WHO’s stated scope.
Begin with a fit-for-purpose analytical method
An instrument name is not a result. A useful test plan starts with the measurand, sample matrix, preparation procedure, reference materials, calibration range and acceptance criteria.
The US FDA’s final guidance on validation and verification of analytical testing methods for tobacco products is written for regulatory submissions, not as a universal factory certification. Its central lesson is still useful: data are only defensible when the method is shown to be suitable for its intended use.
- Identity: What compound or material is the method intended to detect?
- Performance: Are selectivity, accuracy, precision and reporting limits documented?
- Controls: Do blanks, standards and quality-control samples behave as expected?
- Change control: Is the method reassessed when the formulation, instrument or sample preparation changes?
Turn laboratory results into batch controls
A chromatogram becomes operationally useful only when it is connected to specifications, lot records and a documented response to deviations. Teams need to know which result releases a raw material or finished batch, who reviews it, how an out-of-specification result is investigated and which records connect the result to the affected lots.
FDA’s current tobacco rules index continues to identify the agency’s tobacco product manufacturing-practice action as a proposed rule. It should not be presented as a finalized e-liquid manufacturing standard. The proposal nevertheless illustrates practical control themes: established specifications, contamination prevention, traceability, deviation investigation and corrective action.
Separate liquid characterization from aerosol testing
SOP 16 analyzes e-liquid. It does not tell a reader which constituents appear after heating, how much is delivered per puff or how results change across devices. Those questions require a separate aerosol-generation, collection and analytical plan.
FDA’s guide for manufacturers of electronic nicotine delivery systems explains that product applications may need information on harmful or potentially harmful constituents and short-term testing. A defensible study should therefore define the device, coil or pod, power setting, puffing regimen, sample count and analytical endpoints instead of treating one liquid result as a universal performance claim.
Check stability and device compatibility independently
Stability work should use predefined storage conditions, time points, packaging configurations and acceptance criteria. A short accelerated study can flag change, but it should not be converted automatically into a precise shelf-life claim without an appropriate study design and supporting data.
Device compatibility is another distinct question. Testing representative resistance ranges, power settings and atomizer structures can reveal performance differences, but the tested matrix must be disclosed. It cannot establish compatibility with every device. Our related guide on why laboratory scores and consumer preferences can diverge explains the separate role of sensory and use-context testing.
A practical e-liquid quality-control checklist
| Evidence area | Questions to ask |
|---|---|
| Method | What is measured, by which procedure, and for what intended use? |
| Validation | Which performance characteristics, controls and reporting limits are documented? |
| Batch release | What specifications apply, and what happens after a deviation? |
| Stability | Which conditions, intervals, packaging and acceptance criteria support the shelf-life claim? |
| Aerosol | Which device, operating conditions, collection method and analytes were tested? |
| Traceability | Can a result be traced to raw materials, formulation version, production lot and reviewer? |
How to read YTOO’s published claims
YTOO’s source article about its quality-control system says the company operates an 800-square-metre laboratory, maintains more than 30,000 formulations, uses an MES platform and performs device-compatibility work. These are manufacturer-published statements; VAPEAST has not independently audited the facility, database, system configuration or test records.
A prospective buyer can turn those claims into useful due diligence by requesting the applicable method summaries, accreditation scope where relevant, example certificates of analysis, stability protocol, traceability records and the exact device matrix used for validation.
The bottom line
GC-MS remains valuable because it can characterize selected compounds under a defined method. Reliable e-liquid quality control begins when that result is connected to validated procedures, specifications, batch records, stability evidence and product-specific aerosol testing. The strongest claim is not that a laboratory owns an instrument; it is that the evidence chain is defined, reviewable and reproducible.
